News
Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...
Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results